PLRX vs. ARCT, ADCT, RAPP, ORGO, SNDL, IVA, PHAT, AURA, TRDA, and TKNO
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Rapport Therapeutics (RAPP), Organogenesis (ORGO), SNDL (SNDL), Inventiva (IVA), Phathom Pharmaceuticals (PHAT), Aura Biosciences (AURA), Entrada Therapeutics (TRDA), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry.
Pliant Therapeutics vs. Its Competitors
Pliant Therapeutics (NASDAQ:PLRX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.
Arcturus Therapeutics has higher revenue and earnings than Pliant Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arcturus Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Arcturus Therapeutics and 6 mentions for Pliant Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.40 beat Pliant Therapeutics' score of 1.36 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.
Pliant Therapeutics presently has a consensus target price of $13.31, indicating a potential upside of 784.55%. Arcturus Therapeutics has a consensus target price of $53.50, indicating a potential upside of 317.87%. Given Pliant Therapeutics' higher possible upside, research analysts plainly believe Pliant Therapeutics is more favorable than Arcturus Therapeutics.
Pliant Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Arcturus Therapeutics received 375 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. Likewise, 66.42% of users gave Arcturus Therapeutics an outperform vote while only 63.87% of users gave Pliant Therapeutics an outperform vote.
Pliant Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Pliant Therapeutics' return on equity.
Summary
Arcturus Therapeutics beats Pliant Therapeutics on 14 of the 19 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PLRX) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy PLRX Stock Free PLRX Stock Alerts